Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Arsenic trioxide (As(2)O(3)) has shown remarkable efficacy for the treatment of multiple myeloma (MM). Histone deacetylases (HDAC) play an important role in the control of gene expression, and their dysregulation has been linked to myeloma. Especially, HDAC6, a unique cytoplasmic member of class II,...
Main Authors: | Xiaoyan Qu, Juan Du, Chunyang Zhang, Weijun Fu, Hao Xi, Jianfeng Zou, Jian Hou |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3284565?pdf=render |
Similar Items
-
Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
by: Ya-Li Yao, et al.
Published: (2011-01-01) -
Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
by: Zhang Y, et al.
Published: (2020-11-01) -
Synergistic cell killing by concomitant treatment of lung cancer cell line with arsenic trioxide and histone deacetylase inhibitor
by: Ju-Hsien Yao, et al.
Published: (2008) -
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
by: Criselle D'Souza, et al.
Published: (2021-03-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01)